Avingtrans Adaptix secures 510(k) clearance from FDA

Avingtrans plc

Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced that medical imaging technology associate company Adaptix Limited (Adaptix) has received 510(k) clearance from the U.S. Food and Drug Administration for its first orthopaedic medical imaging product.

In 2021, Avingtrans invested £4m in Adaptix, for an 11.9% stake in the business and in December 2022 announced a further investment of £2m by means of a Convertible Loan.

The Board of Adaptix has made the following announcement:

Adaptix, based at Oxford University Science Park, has received 510(k) clearance for its first medical imaging product. The first Adaptix medical product is a Digital Tomosynthesis Orthopaedic imaging system. It is a portable, low-dose imaging system capable of delivering fast, lower-cost, X-ray imaging at the point of patient care. Developed specifically to offer 3D X-ray imaging of hands, elbows and feet at a fraction of the radiation dose and per-study price of traditional CT systems, the system provides clinicians with clearer images than 2D X-ray systems, offering advantages in terms of fewer acquisitions, accelerated patient workflow and enhanced diagnostic accuracy.

Adaptix is already serving veterinary and industrial (Non-Destructive Evaluation) markets using its novel and patent-protected technologies. Receiving the 510(k) clearance is important as it is the first step in Adaptix delivering its mission to transform radiology through provision of innovative truly-portable 3D imaging technologies into healthcare providers.

Mark Evans, CEO of Adaptix, commented:

“We are delighted to receive the 510(k) clearance which allows this innovative technology, and our first medical product, to be marketed in the world’s largest healthcare market. The team are energized by achieving this milestone, and we look forward to delivering enhanced orthopaedic DT imaging systems; a dental DT imaging system; and a chest DT imaging system for Intensive Care and Emergency Department use. We see a future where 3D travels to the patient at the point-of-care throughout hospitals, clinics and primary care transforming patient pathways, improving patient experience, and reducing the cost of care delivery.”

Avingtrans plc designs, manufactures and supplies original equipment, systems and associated aftermarket services to the energy, medical and industrial markets worldwide. 

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Avingtrans builds quantum supply chain opportunity

Avingtrans subsidiary Scientific Magnetics has shipped its 20th quantum computing magnet, with 18 more in production, strengthening its role in the quantum technology supply chain.

Avingtrans Secures Major Medical Milestone With Adaptix CE Certification, Singer Capital Markets

Avingtrans secures CE certification for Adaptix Ortho350, strengthening commercial opportunities in Europe and supporting long term medical growth ambitions.

Avingtrans’ Adaptix Ortho350 receives CE certification

Adaptix can now commercialise its compact 3D orthopaedic imaging system across UK and European healthcare markets.

Avingtrans highlights growing demand in nuclear and digital infrastructure markets

Avingtrans said its Advanced Engineering Systems division is seeing strong growth prospects, supported by renewed investment in nuclear energy, energy security and digital infrastructure, with over £10 million of recent nuclear orders and a broader pipeline in line with market expectations.

Avingtrans CEO Steve McQuillan highlights interim results and future growth areas

Steve McQuillan outlines Avingtrans’ stable first-half results, improved profitability, and expanding opportunities in nuclear energy, data centre cooling, and medical imaging.

Avingtrans Plc Building Momentum in Nuclear and Medical Imaging as Margins Surge (Video)

Avingtrans delivered improved margins and earnings in the first half, supported by stronger aftermarket activity and disciplined debt control. While revenue was flat year-on-year, management expects the usual second-half weighting to return, aided by nuclear contracts and rising data centre cooling demand. With Adaptix now FDA approved and US distributors appointed, medical imaging enters a critical commercial phase alongside growing exposure to AI-driven nuclear build-out.

Search